Find a Provider

Roger B. Cohen, MD Physician

Associate Director of Clinical Research, Abramson Cancer Center
Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Cohen is a Penn Medicine employed physician.

About Dr. R Cohen

Recognized by America's Top Doctors 2011-14

Recognized by Best Doctors in America 2011-2012, 2013-2014

Recognized in Philadelphia Magazine's 2011 through 2015 Top Docs issues

Clinical Specialties

Specialties:

  • Medicine
    • Medical Oncology

Programs & Services:

  • Cancer
    • Lung Cancer
    • Oropharyngeal Cancer
    • Pituitary Cancer
    • Thymus Cancer

Board Certification:

  • Hematology, 1986
  • Internal Medicine, 1984
  • Medical Oncology, 1993

Conditions & Treatments:

  • Laryngeal Cancer
  • Lung Cancer
  • Lung Carcinoid Tumor
  • Mouth Cancer
  • Nasal Cancer
  • Non-Small Cell Lung Cancer
  • Oral Cancer
  • Oropharyngeal Cancer
  • Sinus Cancer
  • Small Cell Lung Cancer
  • Throat Cancer
  • Thyroid Cancer
  • Tongue Cancer

Practice Locations and Appointments

  • Lung Cancer

    Abramson Cancer Center Perelman Center for Advanced Medicine, West Pavilion, 2nd Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

  • Head and Neck Oncology

    Abramson Cancer Center Perelman Center for Advanced Medicine, West Pavilion, 2nd Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Harvard Medical School
Residency: Mount Sinai Medical Center
Fellowship: Mount Sinai Medical Center
Fellowship: National Cancer Institute

Memberships

American Association for Cancer Research, National American Society of Clinical Oncology, National Cerulean Pharmaceuticals, Medical Advisory Board, National Eastern Cooperative Oncology Group, National Heat Biologics, National Millennium Pharmaceuticals Discovery Oncology Scientific Advisory Board, National

Affiliation

Dr. Cohen is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Selected Publications:

Chiorean EG, Hurwitz HI, Cohen RB, Schwartz JD, Dalal RP, Fox FE, Gao L, Sweeney CJ.: Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Ann Oncol 26 (6): 1230-7,2015.

Kaczmar John M, Tan Kay See, Heitjan Daniel F, Lin Alexander, Ahn Peter H, Newman Jason G, Rassekh Christopher H, Chalian Ara A, O'Malley Bert W, Cohen Roger B, Weinstein Gregory S: HPV-related oropharyngeal cancer: risk factors for treatment failure in patients managed with primary surgery (TORS). Head & neck : 2014.

Mateo J, Berlin J, de Bono J S, Cohen R B, Keedy V, Mugundu G, Zhang Lianglin, Abbattista A, Davis C, Gallo Stampino C, Borghaei H: A first-in-human study of the anti-a5ß1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. Cancer chemotherapy and pharmacology 74 (5): 1039-46,2014.

Infante Jeffrey R, Dees E Claire, Olszanski Anthony J, Dhuria Shyeilla V, Sen Suman, Cameron Scott, Cohen Roger B: Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 32 (28): 3103-10,2014.

Lukens J Nicholas, Lin Alexander, Gamerman Victoria, Mitra Nandita, Grover Surbhi, McMenamin Erin M, Weinstein Gregory S, O'Malley Bert W, Cohen Roger B, Orisamolu Abimbola, Ahn Peter H, Quon Harry: Late consequential surgical bed soft tissue necrosis in advanced oropharyngeal squamous cell carcinomas treated with transoral robotic surgery and postoperative radiation therapy. International journal of radiation oncology, biology, physics 89 (5): 981-8,2014.

Academic Contact Info

Division of Hematology-Oncology
Department of Medicine
University of Pennsylvania School of Medicine

Philadelphia, PA 19104
Phone: (215) 662-4469
Patient appointments: 800-789-PENN (7366)